Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
21.47
+0.16 (0.75%)
Jun 29, 2026, 12:00 PM EDT - Market open

Syndax Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Syndax Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $39. The average 1-year stock price forecast is 81.65% higher than the current stock price, while the lowest is $29 (+35.07%) and the highest is $57 (+165.49%).

Price Target: $39 (+81.65%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$29$39$37$57
Change+35.07%+81.65%+72.33%+165.49%

Analyst Ratings

The average analyst rating for Syndax Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy121111111111
Buy222222
Hold000000
Sell000000
Strong Sell000000
Total141313131313

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Stifel Nicolaus
Stifel Nicolaus
Buy
Maintains
$46
BuyMaintains$46+114.25%Jun 15, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$40
BuyReiterates$40+86.31%Jun 15, 2026
Guggenheim
Guggenheim
Buy
Maintains
$34$31
BuyMaintains$34$31+44.39%Jun 12, 2026
Goldman Sachs
Goldman Sachs
Buy
Maintains
$34
BuyMaintains$34+58.36%Jun 4, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
$29
BuyMaintains$29+35.07%May 21, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
344.51M
from 172.35M
Increased by 99.89%
Revenue Next Year
502.75M
from 344.51M
Increased by 45.93%
EPS This Year
-1.70
from -3.29
EPS Next Year
-0.56
from -1.70
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
139.71M--23.68M172.35M344.51M
Revenue Growth
9,109.56%---627.84%99.89%
Gross Profit
139.71M-118.50M-163.03M-218.79M-93.40M318.41M
Gross Margin
100.00%---923.96%-54.19%92.43%
Operating Income
26.22M-151.76M-229.95M-339.67M-273.08M-121.84M
Net Income
24.93M-149.34M-209.36M-318.76M-285.42M-151.13M
EPS
-----3.29-1.70
Free Cash Flow
32.03M-76.27M-82.37M-155.26M-209.80M-34.90M
No. Analysts
-----12
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High379.3M
Avg344.5M
Low298.5M

Revenue Growth

Revenue Growth202620272028
High
120.1%
Avg
99.9%
Low
73.2%

EPS Forecast

EPS202620272028
High-1.16
Avg-1.70
Low-2.71

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-